N,N-dimethyl-6-bromohexanamide | 22809-42-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N-dimethyl-6-bromohexanamide
• 英文别名: 6-bromohexanoic acid dimethylamide；6-bromo-N,N-dimethylhexaneamide；6-bromo-N,N-dimethylhexanamide；N,N-dimethyl-6-bromohexylamide；N,N-dimethyl 6-bromohexanoylamide
• CAS: 22809-42-3
• 化学式: C₈H₁₆BrNO
• 分子量: 222.125
• InChiKey: RDKBNVSQFBZMAE-UHFFFAOYSA-N

物化性质

• 沸点：
  278.5±23.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-6-bromohexanamide 在 potassium carbonate 、 三氯氧磷 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 4-amino-5-chloro-2-methoxy-N-((1-(6-(1-methyl-1 H-indol-3-yl)-6-oxohexyl)piperidin-4-yl)methyl)benzamide
  参考文献：
  名称：

  Design and synthesis of orally active benzamide derivatives as potent serotonin 4 receptor agonist

  摘要：

  A series of 4-amino-5-chloro-2-methoxy-N-(piperidin-4-ylmethyl)benzamide derivatives bearing an aralkylamino, alkylamino, benzoyl or phenylsulfonyl group at its side chain part at the I-position on the piperidine ring was synthesized. They were evaluated for serotonin 4 (5-HT4) receptor agonist activity by testing their ability to contract the isolated guinea-pig ascending colon. 4-Amino-5-chloro-2-methoxy-N-[1-[5-(1-methylindol-3-ylcarbonylamino)pentyl]piperidin-4-ylmethyl]benzamide (1a, Y-34959) and its related compounds possessed favorable pharmacological profiles for gastrointestinal motility. Unfortunately, the compound 1a showed low bioavailability when given orally presumably due to its poor intestinal absorption rate. Replacement of the 1-methylindol-3-yl carbonylamino moiety of 1a with an aralkylamino (or alkylamino) group did not improve the intestinal absorption rate. Replacement of the 1-methylindol-3-ylcarbonylamino moiety with a benzoyl or phenylsulfonyl group increased the intestinal absorption rate compared with 1a. These compounds revealed good pharmacological profiles for gastrointestinal motility and were superior to 1a in oral bioavailability. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00412-7
• 作为产物：
  描述：

  6-溴己酰氯 在 二甲胺 作用下， 以 四氢呋喃 为溶剂， 生成 N,N-dimethyl-6-bromohexanamide
  参考文献：
  名称：

  4-[diaryl)hydroxymethyl]-1-piperidinealkylcarboxylic acids, salts and

  摘要：

  新化合物在过敏性疾病治疗中有用，化学式为：##STR1## 其中Ar和Ar.sup.1为吡啶基、苯基或取代苯基，Y为--OH、--O.sup..crclbar. M.sup..sym. m、--O--较低烷基、--O--芳基或NR.sup.1 R.sup.2（R.sup.1、R.sup.2为H、较低烷基、芳基）在此披露。

  公开号：

  US05057524A1

文献信息

• Cyclopropylamines from N,N-Dialkylcarboxamides and Grignard Reagents in the Presence of Titanium Tetraisopropoxide or Methyltitanium Triisopropoxide
  作者：Armin de Meijere、Vladimir Chaplinski、Harald Winsel、Markus Kordes、Björn Stecker、Vesta Gazizova、Andrei I. Savchenko、Roland Boese、Farina Schill née Brackmann

  DOI：10.1002/chem.201001550

  日期：2010.12.10

  Thirty‐three different N,N‐dialkyl‐ and N‐alkyl‐N‐phosphorylalkyl‐substituted carboxamides 9–17 were treated with unsubstituted as well as with 2‐alkyl‐, 2,2‐dialkyl‐, and 3‐alkenyl‐substituted ethylmagnesium bromides 6 in the presence of stoichiometric amounts of titanium tetraisopropoxide or methyltitanium triisopropoxide to furnish substituted cyclopropylamines 20–25 in 20–98 % yield, depending

  三十三个不同Ñ，ñ -二烷基和ñ -烷基- Ñ -phosphorylalkyl取代羧酰胺9 - 17用未取代的治疗以及用2-烷基- ，2,2-二烷基，和3-链烯基取代乙基镁溴化物6中的化学计量的量的四异丙醇钛或三异丙醇methyltitanium到配料取代环丙胺的存在下20 - 25中20-98％的产率，根据与没有取代基（1：1），优（> 25：1）非对映选择性。通常，环丙胺20 – 28的产率更高（高达98％）用甲基异丙醇三异丙醇钛作为钛介质，获得了非对映选择性的损失。在这些条件下，即使二氧戊环保护的酮，卤素取代的和手性的以及非手性的烷氧基烷基取代的羧酰胺也可以转化为相应的取代的环丙胺，以及未取代的苯基，以及各种烷基取代的乙基溴化镁。多种含杂原子的（例如，被卤素，三苯甲基氧基，四氢吡喃氧基取代）的格氏试剂（共62个实例）。在甲基异丙醇钛存在下，用乙基溴化镁将N，N-二甲酰基烷基胺54转
• A New Versatile Reagent for the Synthesis of Cyclopropylamines Including 4-Azaspiro[2.n]alkanes and Bicyclo[n.1.0]alkylamines
  作者：Vladimir Chaplinski、Harald Winsel、Markus Kordes、Armin de Meijere

  DOI：10.1055/s-1997-17828

  日期：——

  The reaction of dialkylcarboxamides 1 with 1 equiv. of methyltriisopropyloxytitanium together with only 1.1 equiv. of a Grignard reagent gives cyclopropylamines 3 in better yields than the previously published method with 2 equiv. of Grignard reagent and 1 equiv. of Ti(OiPr)4. This new protocol can be applied to intramolecular reactions with in situ generation of the Grignard reagent from ω-bromo-N,N-dimethylhexanamide and methyl ω-bromohexanoate yielding the expected 1-dimetehylaminocyclo[4.1.0]hexane 15 and the corresponding alcohol 18. Cyclohexylmagnesium bromide or chloride transforms N,N-dibenzylformamide and ethyl acetate to 7-exo-N,N-dibenzylaminonorcarane and 7-exo-hydroxy-7-methylnorcarane. N-Methyl-ℇ-caprolactam 25b and even the strained N-benzylpropiolactam 25a were converted to the spirocyclopropanated heterocycles 26a,b.

  二烷基羧酰胺1与等摩尔的三异丙氧甲基钛反应，结合仅1.1摩尔的格氏试剂，所得环丙胺3的产率优于之前发布的方法，该方法使用2摩尔的格氏试剂和1摩尔的Ti(OiPr)4。这种新方案可用于酰胺内分子反应，通通过ω-溴-N,N-二甲基己酰胺和甲基ω-溴己酸酯原位生成格氏试剂，获得预期的1-二甲氨基环[4.1.0]己烷15及相应的醇18。环己基溴镁或氯镁可将N,N-二苯甲基甲酰胺和乙酸乙酯转化为7-exo-N,N-二苯甲基氨基诺卡烷和7-exo-羟基-7-甲基诺卡烷。N-甲基-ε-己内酯25b，甚至是应变较大的N-苄基丙烯内酯25a，均可转化为螺环丙烷化的杂环化合物26a,b。
• Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or
  申请人：Novo Nordisk A/S

  公开号：US06080754A1

  公开（公告）日：2000-06-27

  The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.

  本发明涉及公式I的治疗活性化合物，其制备方法以及含有该化合物的药物组合物。这些新型化合物在预防或治疗与雌激素相关的疾病或综合症方面具有用处。
• BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0873990A1

  公开（公告）日：1998-10-28

  A benzoic acid compound of the formula wherein each symbol is as defined in the specification, an optical isomer thereof and a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising this compound and a pharmaceutically acceptable additive, a serotonin 4 receptor agonist comprising this compound as an active ingredient, a gastrointestinal prokinetic agent and a therapeutic agent for gastrointestinal diseases. The compound of the present invention shows selective and high affinity for serotonin 4 receptors, activates same, is useful as a pharmaceutical agent for the prophylaxis and treatment of gastrointestinal diseases (e.g., reflux esophagitis; gastroesophageal reflux such as that accompanying cystic fibrosis; Barrett syndrome; intestinal pseudoileus; acute or chronic gastritis; gastric or duodenal ulcer; Crohn's disease; non-ulcer dyspepsia; ulcerative colitis; postgastrectomy syndrome; postoperative digestive function failure; delayed gastric emptying caused by gastric neurosis, gastroptosis, diabetes, and the like; gastrointestinal disorders such as indigestion, meteorism, abdominal indefinite complaint, and the like; constipation such as atonic constipation, chronic constipation, and that caused by spinal cord injury, pelvic diaphragm failure and the like; and irritable bowel syndrome), central nervous disorders (e.g., schizophrenia, depression, anxiety, disturbance of memory and dementia), cardiac function disorders (e.g., cardiac failure and myocardial ischemia), urinary diseases (e.g., dysuria caused by urinary obstruction, ureterolith, prostatomegaly, spinal cord injury, pelvic diaphragm failure, etc.), and shows superior absorption.

  式中的苯甲酸化合物 其中各符号如说明书中所定义，其光学异构体及其药学上可接受的盐。由该化合物和药学上可接受的添加剂组成的药物组合物、以该化合物为活性成分的血清素 4 受体激动剂、胃肠促动力药和胃肠疾病治疗剂。 本发明的化合物对 5-羟色胺 4 受体具有选择性和高亲和力，能激活 5-羟色胺 4 受体，可用作预防和治疗胃肠道疾病（如反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎）的药物、反流性食管炎；胃食管反流，如伴随囊性纤维化的胃食管反流；巴雷特综合征；肠道假膜；急性或慢性胃炎；胃或十二指肠溃疡；克罗恩病；非溃疡性消化不良；溃疡性结肠炎；胃切除术后综合征；术后消化功能衰竭；胃神经官能症、胃下垂、糖尿病等引起的胃排空延迟；消化不良、陨石症、腹部不适等胃肠道疾病；失张性便秘、慢性便秘、脊髓损伤引起的便秘、骨盆膈肌功能衰竭等便秘；肠易激综合征）、中枢神经紊乱（如溃疡性结肠炎g.,精神分裂症、抑郁症、焦虑症、记忆障碍和痴呆症）、心脏功能紊乱（如心力衰竭和心肌缺血）、泌尿系统疾病（如尿路梗阻、输尿管结石、前列腺肥大、脊髓损伤、盆腔膈肌衰竭等引起的排尿困难），并显示出良好的吸收性。
• Quinazoline derivative
  申请人：CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.

  公开号：US10421754B2

  公开（公告）日：2019-09-24

  Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

  本文提供了一种喹唑啉衍生物、一种含有该衍生物的药物组合物、一种制备该衍生物的方法以及该衍生物作为抗癌药物的应用。